ClinicalTrials.gg

Program

ABBV-1480

A development code. Also written as “Telisotuzumab adizutecan plus RC148(ABBV-1480)”.

In AbbVie's pipeline, PD-1, VEGF. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 3, since Aug 7, 20262 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 3since Aug 7, 2026Aug 7, 2026Dec 2029phase 3 · NCT07756645
RemeGen11 open or runningphase 2since Sep 30, 2026Sep 30, 2026Dec 2027phase 2 · NCT07874282
  • Named in AbbVie’s own pipeline as ABBV-1480 (RC148), phase 3, as of Jul 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2026First study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to AbbVieAbbVie · NCT07756645 · 940 planned · United States, Puerto Rico
  2. Sep 30, 2026RemeGen's first study: phase 2 study in Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or CytologyNew to RemeGenRemeGen · NCT07874282 · 200 planned · China

Ahead

  1. Dec 2027Primary completion: phase 2 study in Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or CytologyRemeGen · NCT07874282
  2. Dec 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT07756645

TargetBeta

“PD-1, VEGF”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07874282Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology · China2Not yet recruitingRemeGenDec 2027200
NCT07756645Carcinoma, Non-Small-Cell Lung · United States, Puerto Rico3RecruitingAbbVieDec 2029940

How it is read

Names in the registry

  • “Telisotuzumab adizutecan plus RC148(ABBV-1480)”, 2 entries
  • “ABBV-1480”, 1 entry

Codes read as this program: ABBV1480.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.